Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Flurbiprofen
Drug ID BADD_D00941
Description Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.
Indications and Usage Flurbiprofen tablets are indicated for the acute or long-term symptomatic treatment of rheumatoid arthritis, osteorarthritis and anklosing spondylitis. It may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e.g. bursitis, tendonitis, soft tissue trauma). Topical ophthalmic formulations may be used pre-operatively to prevent intraoperative miosis.
Marketing Status Prescription; Discontinued
ATC Code M01AE09; M02AA19; R02AX01; S01BC04
DrugBank ID DB00712
KEGG ID D00330
MeSH ID D005480
PubChem ID 3394
TTD Drug ID D0A1PX
NDC Product Code 63629-8808; 45865-918; 66577-029; 62756-510; 43063-992; 63275-9913; 38779-2739; 68071-4436; 51927-0008; 68788-7341; 55545-0405; 63629-8338; 22568-1093; 68071-2480; 0395-8053; 38779-0362; 51552-0818; 0093-0711; 51686-0004; 49452-3178; 62991-3064; 51927-0219; 61891-001; 17511-123
Synonyms Flurbiprofen | 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic Acid | Flubiprofen | Fluriproben | Dobrofen | E-7869 | E 7869 | E7869 | Nu-Flurbiprofen | Nu Flurbiprofen | Ocufen | ratio-Flurbiprofen | ratio Flurbiprofen | Strefen | Flugalin | Flurbiprofen Sodium | Froben | Neo Artrol | Novo-Flurprofen | Novo Flurprofen | Ansaid | Apo-Flurbiprofen | Apo Flurbiprofen | BTS-18322 | BTS 18322 | BTS18322 | Cebutid | Froben SR | Ocuflur
Chemical Information
Molecular Formula C15H13FO2
CAS Registry Number 5104-49-4
SMILES CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.0020.014548%
Acute febrile neutrophilic dermatosis01.02.01.006; 23.03.03.0330.009698%Not Available
Agranulocytosis01.02.03.001--Not Available
Albuminuria20.02.01.001--Not Available
Alopecia23.02.02.001--
Amblyopia06.02.01.001--Not Available
Amnesia17.03.02.001; 19.20.01.001--
Anaemia01.03.02.001--
Anaphylactic reaction10.01.07.001; 24.06.03.0060.019397%
Anaphylactic shock10.01.07.002; 24.06.02.0040.009698%Not Available
Angina pectoris02.02.02.002; 24.04.04.002--
Angioedema10.01.05.009; 23.04.01.0010.058191%Not Available
Anxiety19.06.02.002--
Aplastic anaemia01.03.03.002--Not Available
Arrhythmia02.03.02.001--Not Available
Arthritis15.01.01.001--
Arthropathy15.01.01.003--Not Available
Asthenia08.01.01.001--Not Available
Asthma10.01.03.010; 22.03.01.002--Not Available
Ataxia08.01.02.004; 17.02.02.001--
Bladder pain20.02.02.001--Not Available
Bleeding time prolonged13.01.02.002--Not Available
Blepharitis06.04.04.001; 23.03.04.012--Not Available
Blood uric acid increased13.02.04.001--Not Available
Body temperature increased13.15.01.001--Not Available
Breast pain21.05.05.003--
Bronchitis11.01.09.001; 22.07.01.001--
Bronchospasm10.01.03.012; 22.03.01.0040.009698%
The 1th Page    1 2 3 4 5    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene